Navigation Links
ABX Pentra XL 80

ProductsABX Pentra XL 80
Company Horiba ABX
Item ABX Pentra XL 80
Features 
  • Auto-sampling.
  • 5-part differential.
  • Customized dilution ratio.
  • Automatic sample re-run.
  • 26 parameters.
  • Patient data management adapted to your specific needs.
  • Optimized sample processing, ideal for workloads up to 350 samples/day.
  • Fully integrated validation station.
  • Completely automated and easy access to all menus.
Description In response to the needs of its users for onboard data management and automated sample dilution, ABX has launched the latest development in its haematology analyser range, the PENTRA XL 80. In addition to these unique new features, the PENTRA XL 80 incorporates all the key features of the PENTRA 80 including fully automated throughput of 80 samples per hour to provide a CBC + DIFF leucocyte count with over 26 parameters. The new Customised Dilution Ratio (CDR) of the PENTRA XL 80 uniquely enables automatic linearity extension and completely removes the need for manual dilution of out-of-range samples. The CDR pushes back the linearity limits with a choice of three different ratios (1/2, 1/3, 1/5) for over range samples without any operator intervention.

To provide a complete solution to laboratory requirements by treating haematology workflow with intelligence, the PENTRA XL 80 also incorporates a cutting edge fully integrated data management system that enables onboard validation of results. The Integrated Validation Station automatically provides report validation and positive and negative Delta check flagging. In addition, it undertakes patient reporting using selective results for mixing from run, re-run and manual entry.

The new analyser is also ideal for micro sampling, since the technology behind the PENTRA XL 80 is based on a patented double sampling needle and MDSS technology which results in very low sample volumes - 30l for CBC (53l for CBC+DIFF). Furthermore, as both rack and sample barcodes are read, the PENTRA XL 80 guarantees accurate sample identification. Equally importantly, end-over-end rotation of tubes prior to sampling ensures optimal sample homogenisation and result quality.

Info Horiba ABX
Customer Service: (888) 903-5001
Web site: http://www.horiba-abx.com/gb/

Related medicine products :

1. ABX Pentra 60
2. ABX Pentra 120 SPS
3. ABX Pentra 60 C+
4. ABX Pentra 80
5. ABX Pentra DX 120
6. ABX Pentra 400
7. ABX Pentra DF 120
TAG: ABX Pentra
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...Sunday underwent a health check-up at the All Indi...s medical reports are satisfactory and he is in go...inister's Office (PMO). "The prime minister reach...at about 11 a.m. He underwent an echo test for the...
...er which leads to various other problems like hype... few. // Type 2 diabetes is a disease caused larg... to researchers in South Korea, there has been an ...ng the disease. Sedentary lifestyles coupled with ...
... fake medicines, most of them from India, were sei...according to officials here. The fake medicines i...cer and high cholesterol and condoms. A sample tha...was being passed off as a cardiovascular drug cont...
...eloped a new method that advocates the use of a ga... D. Karunagaran, a professor at the department of...gy (IIT) in Madras, and Suby Oommen, a PhD student...hnology in Kerala, have been working on garlic-bas...
Other Medicine News:Health News:Garlic compound may help treat cancer 2
(Date:9/3/2008)... analysis showed that Multaq(R) (dronedarone) decr...rial fibrillation or atrial flutter already ...y, BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCa...ata from the ATHENA study were presented today at,...Society of Cardiology,congress 2008, in Munich, Ge...
(Date:9/3/2008)...mpany Focuses Operations, Updates Zingo Launch Pro...on Strategy Conference Call Today...t. 3 /- Anesiva,Inc. (Nasd...restructure,operations to focus on commercial and ...ransition to a specialty pharmaceutical pain manag...
(Date:9/3/2008)...B-509 to be Evaluated in Repeat-Dosing Study in Su...swire-FirstCall/ -- Sangamo,BioSciences, Inc. (Nas...Phase,2 clinical trial (SB-509-801) to evaluate it...e, degenerative motor-neuron disease for which the...ngamo,s drug, SB-509, is an injectable formulation...
(Date:9/2/2008)...W YORK, Sept. 3 /- Forest L...lmirall, S.A. today announced results from,two glo...el long-acting,inhaled anticholinergic for the tre...ary disease (COPD). In both the ACCLAIM/COPD I&II,...Safety In Moderate to,Severe COPD Patients) studie...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Indivumed Appoints Annette Kassen as Vice President Clinical Research 4500 1Indivumed Appoints Annette Kassen as Vice President Clinical Research 4500 2Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 1Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 2Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 3Module map links embryonic stem cells and cancer stem cells 16381 1Module map links embryonic stem cells and cancer stem cells 16381 2 26 23163 3B7 5m to transform patient care 16379 1 26 23163 3B7 5m to transform patient care 16379 2 26 23163 3B7 5m to transform patient care 16379 3
...clinical data for potential combination,therapies ...after,ITMN-191 exposure, BARCELONA, Spain, April 1...announced today the presentation of findings from,...ease inhibitor,ITMN-191, alone or in combination w... the European Association for the Study of the,Liv...
...SS WIRE)--Apr 11, 2007 - New data,supporting the c...,the most advanced investigational oral protease i...HCV) infection, will be presented,at the 42nd Annu...dy of the Liver (EASL) in Barcelona this week. In ...een accepted for presentation,at the EASL conferen...
Other Medicine Technology:InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6